Journal Browser

Journal Browser

Molecular Research of Hepatitis C Virus Infection

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 30 May 2024 | Viewed by 525

Special Issue Editor

Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, 69434 Lyon, France
Interests: hepatitis viruses; antivirals; virus–host interactions; pathogenesis; hepatocellular carcinoma

Special Issue Information

Dear Colleagues, 

Almost 10 years have passed since the introduction of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV). Nonetheless, HCV infection still continues to be one of the most important public health burdens worldwide, with more than 58 million persons living with the virus in 2019, accounting for approximately 399,000 deaths in the same year due to cirrhosis and hepatocellular carcinoma (HCC), according to the WHO. HCV is a member of the Flaviviridae family, containing as a genome a positive stranded RNA of ~ 9.6 kB encoding a large polyprotein of about 3000 amino acids, which is processed by viral and cellular proteases into three structural (E1, E2, core) and seven non-structural proteins (p7, NS2, NS3, N4A, NS4B, NS5A, NS5B). Thanks to molecular research on HCV, including the cloning of the genome, the establishment of a “subgenomic replicon” system, and, later on, of a cell culture replicative virus (HCVcc), the roles of the viral proteins have been deciphered as well as the main steps of the viral replication cycle. This has paved the way for the discovery of a curative therapy based on DAAs such as sofosbuvir (acting on the viral polymerase NS5B) and daclatasvir (acting on NS5A), which can clear HCV in more than 95% of patients. However, the fight against HCV is not over due to insufficient treatment coverage (20% of carriers are diagnosed and 13% are treated, according to the WHO), especially in middle- and low-income countries, and the lack of a vaccine. Moreover, resistant variants may appear that can compromise the use of current drugs, and some people who have cleared the virus after a prolonged HCV infection may also still develop liver cancer.

The scope of this Special Issue entitled “Molecular Research of Hepatitis C Virus Infection” is to try to answer the questions that still remain open, such as the following: What are the precise molecular mechanisms of virus-induced HCC? What are the molecular determinants of HCC after an HCV cure? Where do we stand with the development of an HCV vaccine or with the discovery of cellular targets for novel antiviral approaches?

Dr. Boyan Grigorov
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • HCV
  • virus replication and pathogenesis
  • antivirals
  • virus–cell interaction
  • vaccine development
  • hepatocellular carcinoma

Published Papers

This special issue is now open for submission.
Back to TopTop